Previous 10 | Next 10 |
Q BioMed ( OTCQB:QBIO +1.3% ) announced today that it entered an exclusive Named Patient Program distribution agreement with Caligor Coghlan Pharma Services for its non-opioid metastatic cancer bone pain drug, Strontium, 89. More news on: Q BioMed Inc., Healthcare stocks news R...
NEW YORK , July 8, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today it has entered into an exclusive Named Patient Program distribution agreement for its non-opioid metastatic cancer bone pain drug, Strontium89 , with Caligor Cog...
NEW YORK , June 30, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, today issued a letter to shareholders. Dear Fellow Shareholders, We are extremely pleased to have reached our initial goal of becoming a commercial pharmaceutical compan...
NEW YORK , June 12, 2020 /PRNewswire/ -- Q BioMed (OTC: QBIO) is proud to be a Supporter of the Living Beyond Breast Cancer ( LBBC ) 2020 Virtual Conference on Metastatic Breast Cancer taking place June 13 and 14, 2020. Over 1,100 patients will be participating in this virtual confere...
NEW YORK , May 15, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announces the launch of its marketing campaign for its FDA approved non-opioid metastatic bone pain drug Strontium89 (Strontium Chloride Sr-89 Injection, USP). A product websi...
NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and Q BioMed Inc. (OTCQB: QBIO) (the "Company"), a commercial stage biotechnology company, announced today that a new audio interview with the Company is now available. The interview featuring an overview of QBIO&...
Phoenix, Arizona--(Newsfile Corp. - April 27, 2020) - The Stock Day Podcast welcomed Q BioMed Inc. (OTCQB: QBIO) ("the Company"), a biotech acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. CEO of the Company, D...
April 22, 2020 Palm Beach, FL – April 22, 2020 – The question heard around the world is “When will a coronavirus vaccine be ready?”. Its not an “if” but a “when” and that “when” from all accounts will most...
NEW YORK , April 22, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, today announced that together with its technology partner, Mannin Research, they are accelerating the rapid development of novel drugs for the treatment of life-threatening ...
Q BioMed ( OTCQB:QBIO ) has entered into a financial transaction with Yorkville Advisors Global (YA). More news on: Q BioMed Inc., Read more ...
News, Short Squeeze, Breakout and More Instantly...
Veradigm Inc. (MDRX) is expected to report $0.17 for Q3 2023 Aperam SA New York Shares (APEMY) is expected to report for Q3 2023 HTG Molecular Diagnostics Inc. (HTGMQ) is expected to report for Q3 2023 Enel Spa ADR (ENLAY) is expected to report for Q3 2023 Firm Capital Property Tr...
Impac Mortgage Holdings, Inc. (IMPM) is expected to report for quarter end 2023-09-30 Westbury Bancorp Inc (WBBW) is expected to report for quarter end 2023-09-30 Aldeyra Therapeutics Inc. (ALDX) is expected to report $-0.24 for Q3 2023 Zalando SE ADR (ZLNDY) is expected to report for...
thyssenkrupp AG (TYEKF) is expected to report for Q4 2023 Azul S.A. American Depositary Shares (each representing three preferred shares) (AZUL) is expected to report $-0.38 for Q3 2023 Bath & Body Works Inc. (BBWI) is expected to report $0.36 for Q3 2024 Johnson Controls Internat...